Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2765 SEK | -3.83% |
|
-7.37% | -97.24% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB